| Trial ID: | L4761 |
| Source ID: | NCT06224790
|
| Associated Drug: |
Pirfenidone
|
| Title: |
Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
|
| Acronym: |
PenDaNt
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Nephropathies|Type 2 Diabetes
|
| Interventions: |
DRUG: Pirfenidone|OTHER: Placebo
|
| Outcome Measures: |
Primary: 15% improvement in eGFR, eGFR of the patients shall be evaluated for at least 15% improvement, 6 months | Secondary: Safety - Adverse Effects of Drugs, Adverse Effects of the drugs, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Sidrah Lodhi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-03-10
|
| Completion Date: |
2025-03-07
|
| Results First Posted: |
|
| Last Update Posted: |
2025-03-11
|
| Locations: |
King Edward Medical University, Lahore, Punjab, 54000, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT06224790
|
